ADC Linker

Ald-Ph-amido-PEG3-C-COOH is a noncleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates stable attachment between the antibody and the cytotoxic drug, ensuring effective delivery to target cells. Its structure supports the development of ADCs for enhanced therapeutic efficacy in various cancers and other diseases.

Boc-PEG6-Val-Cit-PAB-OH is an ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing targeted delivery and efficacy in cancer research applications. Its hydrophilic PEG6 spacer promotes solubility and stability in biological systems, making it an essential tool in the development of novel cancer therapeutics.

Boc-aminooxy-ethyl-SS-propanol is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the selective release of cytotoxic agents upon internalization, enhancing the therapeutic efficacy of ADCs. This compound is critical for research applications focused on developing targeted cancer therapies.

DMAC-SPDB is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic drugs to antibodies, enhancing the targeted delivery and efficacy of chemotherapeutic agents. DMAC-SPDB is instrumental in advancing research in cancer therapeutics and ADC development.

PDdB-Pfp is a cleavable antibody-drug conjugate (ADC) linker designed for targeting the extracellular loop 1 (ECL1) of transmembrane 4 L6 family member 1 (TM4SF1). It facilitates the delivery of cytotoxic agents to specific cells expressing TM4SF1, enabling enhanced therapeutic efficacy while minimizing off-target effects. PDdB-Pfp is valuable for research in the development of targeted cancer therapies and other applications involving ADC technology.

Diazido-methyltetrazine tri-arm is a versatile ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective conjugation of cytotoxic agents to antibodies, enhancing therapeutic efficacy while minimizing off-target effects. Its structural features allow for efficient formation of stable linkages, making it suitable for various applications in ADC development and cancer research.

Me-Tet-PEG3-NHBoc is an ADC linker featuring a tetrazine moiety and three polyethylene glycol (PEG) units. This compound can participate in a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) derivatives, facilitating targeted drug delivery in antibody-drug conjugates (ADCs). It is a valuable tool for researchers developing site-specific conjugation methodologies and enhancing the therapeutic efficacy of biologic therapies.

DBCO-PEG2-C2-acid is an efficient ADC linker that facilitates the synthesis of Antibody-Drug Conjugates (ADCs). This compound utilizes the DBCO (dibenzocyclooctyne) chemistry for site-specific conjugation, enhancing the stability and efficacy of the resulting ADCs. It is essential for researchers focused on developing targeted therapies in oncology and other therapeutic areas, allowing for improved drug delivery and minimized off-target effects.

Me-Tet-PEG3-NH2 is an ADC linker featuring three polyethylene glycol (PEG) units. This compound utilizes its tetrazine moiety to engage in a specific inverse electron demand Diels-Alder (iEDDA) reaction with cyclooctene (TCO) derivatives. It serves as a valuable tool in antibody-drug conjugate (ADC) development, facilitating the site-specific conjugation of cytotoxic agents to antibodies for targeted cancer therapy.

Ald-Ph-amido-PEG1-C2-Pfp ester is a non-cleavable 1-unit polyethylene glycol (PEG) linker designed for antibody-drug conjugation (ADC) applications. This linker facilitates the stable attachment of cytotoxic agents to antibodies, thereby enhancing the therapeutic efficacy in targeted cancer treatment. Its use allows for improved pharmacokinetics and minimized systemic toxicity, making it valuable in the development of innovative biopharmaceuticals.

TCO-GK-PEG4-NHS ester is an ADC linker that facilitates the synthesis of [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d, which exhibits high affinity and immunoreactivity for the HER2 target. This compound features a TCO group that participates in inverse electron demand Diels-Alder (iEDDA) click chemistry reactions with tetrazine-containing molecules, allowing for precise bioconjugation applications in targeted therapies. It is suitable for research involving antibody-drug conjugates and the development of advanced molecular imaging techniques.

Acid-propionylamino-Val-Cit-OH is a cleavable linker designed for the development of antibody-drug conjugates (ADCs). It facilitates targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing off-target effects. This compound is widely utilized in cancer research and drug development, allowing for precise control over drug release in therapeutic applications.

Me-Tet-PEG2-NHS is an ADC linker designed for targeted drug delivery. This compound features a tetrazine group capable of participating in inverse electron demand Diels-Alder (iEDDA) reactions with TCO-modified molecules. Its two PEG units enhance solubility and stability, making it suitable for applications in antibody-drug conjugate (ADC) development and bioorthogonal labeling strategies in chemical biology.

BnO-PEG6-OH is a non-cleavable polyethylene glycol (PEG) linker designed for the synthesis of antibody-drug conjugates (ADCs). This 6-unit PEG compound enhances the stability and solubility of ADCs, facilitating targeted drug delivery. Additionally, BnO-PEG6-OH serves as a versatile linker in the development of PROTACs, enabling precise modulation of protein degradation pathways for various research applications.

Me-Tet-PEG4-NHBoc is an ADC linker characterized by the presence of four PEG units and a Tetrazine moiety. It is designed to facilitate a specific inverse electron demand Diels-Alder reaction (iEDDA) with TCO-containing compounds. This functionality enables effective conjugation in antibody-drug conjugate (ADC) applications, enhancing targeted delivery and efficacy in cancer research and other therapeutic areas.

Dimethylamine-SPDB is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent enables the selective release of therapeutic agents upon internalization and subsequent cleavage within target cells, enhancing the efficacy of ADCs. It is particularly useful in research applications focused on targeted cancer therapies and drug delivery systems.

Tr-PEG6-OH is a non-cleavable polyethylene glycol (PEG) linker consisting of six units, designed for use in the synthesis of antibody-drug conjugates (ADCs). This linker provides enhanced solubility and stability, ensuring effective delivery of therapeutic agents while maintaining the binding affinity of the antibody. Tr-PEG6-OH is ideal for research applications focused on the development of targeted cancer therapies and bioconjugation techniques.

SMCC-NH-CH2-triazole-PEG8-oxydiacetamide-Lys(MTT)-PAB is an ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a linker that facilitates the attachment of active pharmaceutical agents to antibodies, enhancing specificity and efficacy in targeted therapy applications. It is suitable for various research applications aimed at developing novel ADC formulations for cancer treatment and other therapeutic areas.

Me-Tet-PEG4-NHS is an ADC linker featuring four PEG units that facilitates targeted drug delivery. This compound contains a Tetrazine moiety, enabling it to undergo a specific inverse electron demand Diels-Alder reaction (iEDDA) with trans-cyclooctene (TCO) derivatives. Its key biological activity lies in enhancing the stability and efficacy of antibody-drug conjugates (ADCs), making it suitable for applications in cancer research and therapeutic development.

L-Val-D-Cit-PAB is an antibody-drug conjugate (ADC) linker that facilitates the synthesis of highly targeted therapeutics. This compound is characterized by its ability to connect antibodies with cytotoxic drugs, enhancing the delivery of biologically active agents to specific cells. L-Val-D-Cit-PAB is particularly useful in cancer research, where it aids the development of ADCs to improve selectivity and efficacy in tumor treatment.

Aminooxy-PEG4-alcohol is a non-cleavable linker that consists of a four-unit polyethylene glycol (PEG) chain, primarily targeting antibody-drug conjugates (ADCs). It serves as a versatile linker in the synthesis of ADCs and can also be employed in the development of proteolysis-targeting chimeras (PROTACs). This reagent enhances the stability and solubility of conjugated drugs, facilitating targeted delivery in therapeutic applications.

SPDB-sulfo is a glutathione-cleavable linker specifically designed for antibody-drug conjugates (ADCs). It facilitates the selective release of cytotoxic agents in tumor cells, enhancing the therapeutic efficacy of the ADCs while minimizing systemic toxicity. This linker is essential in the development of targeted cancer therapies, allowing for precise delivery of drugs to malignant tissues.

DBCO-S-S-acid is a cleavable linker designed for the construction of antibody-drug conjugates (ADCs). It features a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, allowing for selective and efficient conjugation. This reagent is essential in bioconjugation strategies aimed at enhancing targeted therapeutic delivery in cancer research and other therapeutic applications.

PEG12-Tos is a non-cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). This PEG-based linker facilitates the construction of stable ADCs, improving the therapeutic efficacy of the conjugated drug while minimizing off-target effects. In addition, PEG12-Tos serves as a versatile linker in the development of PROTACs, enhancing cell permeability and solubility, and expanding research applications in targeted protein degradation and therapeutic interventions.

Ala-Ala-Asn-PAB is a peptide-cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, thereby enhancing the therapeutic efficacy of ADCs. Researchers can utilize Ala-Ala-Asn-PAB in studies focused on improving drug delivery mechanisms and evaluating the pharmacodynamics of ADC formulations.

Fmoc-NH-ethyl-SS-propionic NHS ester is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. This reagent facilitates the conjugation of therapeutics to antibodies while enabling targeted delivery and controlled release of the drug within the cellular environment. Its unique structure allows for effective cleavage, making it ideal for applications in cancer research and therapeutic development involving ADCs.

N-trifluoroacetyl-β-alanyl chloride is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. Its application in drug development research aids in the creation of targeted therapies for cancer treatment and other diseases.

Propargyl-C8-amido-PEG2-NHS ester is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs) with a primary mechanism of enabling stable conjugation through click chemistry. This reagent contains an alkyne functional group, allowing for efficient copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules. Its application spans the development of targeted therapies by facilitating the precise attachment of cytotoxic drugs to antibodies, enhancing therapeutic efficacy while minimizing off-target effects.

2-Hydroxyethyl disulfide mono-tosylate is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis. It facilitates the selective conjugation of cytotoxic agents to antibodies, enabling targeted delivery to cancer cells. This compound is instrumental in advancing research on ADC formulations and therapeutic strategies in oncology.

DMAC-PDB is a cleavable ADC linker that facilitates the construction of antibody-drug conjugates (ADCs). This reagent is designed to promote targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It serves as a valuable tool in the development of ADCs for cancer research, enabling the precise linking of antibodies to payloads for improved specificity in therapeutic applications.

Me-Tetrazine-Me-Ph-amide-Lys(Boc)-Lys-N3 is an innovative ADC linker that facilitates the construction of antibody-drug conjugates (ADCs). This reagent provides a robust mechanism for site-specific conjugation, enhancing the therapeutic efficacy of ADCs. It is particularly useful in research applications focused on targeted cancer therapies and precision medicine.

Boc-aminooxy-amide-PEG4-propargyl is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis, featuring a 4-unit polyethylene glycol (PEG) backbone. This compound includes an alkyne functional group, facilitating its use in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its robust chemical properties make it suitable for the development of targeted therapies in oncology research and bioconjugation applications.

Bis-SS-C3-sulfo-NHS ester is a cleavable linker designed for the development of antibody-drug conjugates (ADCs). This compound is pivotal in facilitating selective drug delivery by connecting cytotoxic agents to antibodies via a disulfide bond, ensuring targeted release within the tumor microenvironment. It is widely applied in research focused on ADC formulation and optimization strategies in cancer therapeutics.

Mal-amido-PEG9-Val-Ala-PAB-SG3200 is a cleavable linker designed for use in antibody-drug conjugates (ADCs). Its structural features enable selective release of therapeutic agents upon cleavage, enhancing targeted drug delivery. This linker is crucial for research applications focusing on the development and optimization of ADC formulations.

MC-Gly-Gly-Phe-OSu is an ADC linker that facilitates the conjugation of antibody-drug complexes. It demonstrates key biological activity by enhancing the targeting of cytotoxic agents to cancer cells, thereby improving therapeutic efficacy. This compound is primarily utilized in research applications focused on antibody-drug conjugate development for cancer treatment.

AcLys-PABC-VC-Aur0101 intermediate-1 is a cathepsin-cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates targeted drug delivery by ensuring the release of the cytotoxic drug within the tumor microenvironment upon cathepsin-mediated cleavage. It is essential for enhancing the efficacy and specificity of ADCs in cancer therapeutics, providing researchers with a valuable tool for developing novel therapies.

4-Succinimidyl-oxycarbonyl-α-(2-pyridyldithio)toluene functions as a non-cleavable linker in the fabrication of antibody-drug conjugates (ADCs). This compound enables the stable attachment of cytotoxic payloads to monoclonal antibodies, thereby enhancing the therapeutic efficacy of the resulting ADCs. It is particularly useful in developing targeted cancer therapies where the controlled delivery of drugs is paramount for minimizing off-target effects.

Mal-L-Dap(Boc)-OSu is an ADC linker that facilitates the conjugation of antibodies to cytotoxic agents. Its primary mechanism involves forming stable bonds that enhance the efficacy and selectivity of antibody-drug conjugates (ADCs). This reagent is essential for researchers developing targeted therapies in oncology and other applications where precision delivery of therapeutics is critical.

Glucocorticoid receptor agonist-1 phosphate Gly-Glu TFA is a cleavable linker designed for the synthesis of Antibody-Drug Conjugates (ADCs). This compound facilitates targeted drug delivery by linking cytotoxic agents to antibodies, enhancing therapeutic efficacy while minimizing off-target effects. Its ability to be cleaved under specific physiological conditions makes it a valuable tool in the development of precision medicine strategies.

MP-PEG4-VK(Boc)G-OSu is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It provides site-specific attachment of drug molecules to antibodies, allowing for targeted delivery of therapeutics to cancer cells. This linker is particularly valuable in the development of ADCs aimed at enhancing the efficacy and reducing the off-target effects of cancer treatment.

DL002 is an antibody-drug conjugate (ADC) linker designed for the synthesis of conjugates featuring BCL-2 family protein degraders. It plays a critical role in tumor research by facilitating targeted delivery of cytotoxic agents, thereby enhancing therapeutic efficacy. This reagent is essential for studies aiming to investigate the modulation of BCL-2 proteins in cancer treatment strategies.

m-PEG2-Tos is an uncleavable linker targeting antibody-drug conjugates (ADCs). This PEG-based compound facilitates the conjugation of therapeutic agents to antibodies, enhancing delivery and efficacy in targeted therapy. Additionally, m-PEG2-Tos can be utilized as a linker in the synthesis of PROTACs, contributing to the development of tailored degradation strategies in cellular studies.

Propargyl-PEG1-SS-PEG1-PFP ester is a cleavable linker designed for use in antibody-drug conjugates (ADCs), facilitating the targeted delivery of therapeutic agents. Featuring a propargyl group, this reagent allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it particularly useful for bioconjugation applications. Its versatile structure enables enhanced stability and controlled release in therapeutic settings.

Fmoc-Asn-Pro-Val-PABC-PNP is an ADC linker designed for antibody-drug conjugate (ADC) applications. This reagent facilitates the efficient conjugation of cytotoxic agents to antibodies, enhancing targeted delivery to cancer cells. Its structure and properties make it suitable for research in drug development and therapeutic efficacy studies.

Cyclooctyne-O-amido-PEG2-PFP ester is a non-cleavable linker designed for antibody-drug conjugates (ADCs), utilizing a 2-unit polyethylene glycol (PEG) structure. This compound serves as a versatile click chemistry reagent, possessing an alkyne group that enables efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing biomolecules. Its application is critical for the development of targeted therapies, enhancing the delivery and efficacy of cytotoxic agents in ADC formulations.

LC-PEG8-SPDP is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the attachment of therapeutic agents to antibodies, promoting targeted delivery and enhancing the efficacy of treatments. Its biocompatibility and water solubility make it suitable for research applications focused on ADC development and optimization in cancer therapeutics.

Mal-PEG3-VCP-NB is a degradable antibody-drug conjugate (ADC) linker characterized by its maleimide functional group, a three-unit polyethylene glycol (PEG) spacer, and a valine-citrulline (VCP) cleavage site. This compound facilitates site-specific conjugation to antibodies, enhancing the therapeutic efficacy of ADCs while allowing for controlled release of cytotoxic agents. It is primarily utilized in the development of ADCs for targeted cancer therapies.

BCN-exo-PEG2-maleimide is an ADC linker characterized by the presence of two PEG units and a bidentate macrocyclic ligand, BCN. This compound facilitates the formation of stable triazole linkages through click chemistry by reacting with azide-containing molecules, and operates without the need for catalysts. Its maleimide group is hydrolytically labile in aqueous environments, making it suitable for applications in drug delivery and bioconjugation studies.

Propargyl-O-C1-amido-PEG4-C2-NHS ester is a non-cleavable 4-unit PEG linker designed for antibody-drug conjugation (ADC) applications. This compound features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing molecules. Its properties make it suitable for the development of stable and effective ADCs in therapeutic research.

Propargyl-O-C1-amido-PEG3-C2-NHS ester is a non-cleavable PEG-based linker that targets the synthesis of antibody-drug conjugates (ADCs). Featuring an alkyne group, it serves as a click chemistry reagent and is capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. This compound is essential for creating stable ADC structures, enhancing drug delivery and efficacy in therapeutic applications.